EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma

Laura-Sophie Landwehr iD, Barbara Altieri iD, Iuliu Sbiera, Hanna Remde iD, Stefan Kircher, Julie Olabe iD, Silviu Sbiera iD, Matthias Kroiss iD, Martin Fassnacht iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Laura-Sophie Landwehr und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, 97080 Würzburg, Germany. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis in advanced stages. While therapies targeting the checkpoint molecules programmed cell death 1 (PD-1), its ligand PD-L1, and the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have revolutionized treatment in many cancers, the results in ACCs were heterogeneous.

Objective

Their expression in ACC has not been systematically studied and might explain the variable response to immune checkpoint inhibitors.

Methods

The expression of PD-1, PD-L1 and CTLA-4 was examined in 162 tumor samples from 122 patients with ACC by immunohistochemistry (threshold of >1%) and correlated with tumoral T lymphocyte infiltration and clinical endpoints. Finally, univariate and multivariate analyses of progression-free and overall survival were performed.

Results

PD-1 and PD-L1 were expressed in 26.5% and 24.7% of samples, respectively, with low expression in most tumor samples (median positive cells: 2.1% and 21.7%). In contrast, CTLA-4 expression was observed in 52.5% of ACC with a median of 38.4% positive cells. Positive PD-1 expression was associated with longer progression-free survival (HR 0.50, 95% CI 0.25-0.98, P = .04) even after considering prognostic factors. In contrast, PD-L1 and CTLA-4 did not correlate with clinical outcome. Additionally, PD-1 and PD-L1 expression correlated significantly with the amount of CD3+, CD4+, FoxP3+, and CD8+ T cells.

Conclusion

The heterogeneous expression of PD1, PD-L1, and CTLA-4 in this large series of well-annotated ACC samples might explain the heterogeneous results of the immunotherapies in advanced ACC. In addition, PD-1 expression is a strong prognostic biomarker that can easily be applied in routine clinical care and histopathological assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CTLA-4 AntigenAdrenocortical CarcinomaAdrenal Cortex NeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenHumansMaleFemaleMiddle AgedPrognosisAdultAgedBiomarkers, TumorYoung AdultLymphocytes, Tumor-InfiltratingAdolescentAged, 80 and over

Stichwörter der Autor:innen

CTLA-4PD-1PD-L1adrenocortical carcinomaglucocorticoidsimmune checkpointsimmunotherapyprognostic marker

Substanzen

CTLA-4 AntigenProgrammed Cell Death 1 ReceptorB7-H1 AntigenCTLA4 protein, humanPDCD1 protein, humanCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
  • Institute GReD (Genetics, Reproduction and Development), University Clermont Auvergne, 63001 Clermont-Ferrand, France.
  • Comprehensive Cancer Center Mainfranken, University of Würzburg, 97080 Würzburg, Germany.
  • Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 München, Germany.
  • Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.

ORCID-Profile: Laura-Sophie Landwehr, Barbara Altieri, Hanna Remde, Julie Olabe, Silviu Sbiera, Matthias Kroiss, Martin Fassnacht

Förderung

  • German Research Foundation

Zitieren

APA

Landwehr, L. S., Altieri, B., Sbiera, I., Remde, H., Kircher, S., Olabe, J., Sbiera, S., Kroiss, M., & Fassnacht, M. (2024). Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae109

Vancouver

Landwehr LS, Altieri B, Sbiera I, Remde H, Kircher S, Olabe J, et al. Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae109

BibTeX
@article{Landwehr2024,
  author = {Landwehr, Laura-Sophie and Altieri, Barbara and Sbiera, Iuliu and Remde, Hanna and Kircher, Stefan and Olabe, Julie and Sbiera, Silviu and Kroiss, Matthias and Fassnacht, Martin},
  title = {Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae109}
}
Kostenlos starten →